SCHEMBL3330837

SCHEMBL3330837

Cc1cc(-c2cc(-c3ccc(C(=O)NC4CCCCCC4)cc3)[nH]c(=O)n2)ccc1O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 2/20 0.60
CDC7 O00311 1/20 0.60
CSNK2A2 P19784 1/20 0.60
CLK1 P49759 1/20 0.60
GSK3B P49841 1/20 0.60
CSNK2B P67870 1/20 0.60
CSNK2A1 P68400 1/20 0.60
CSNK2A3 Q8NEV1 1/20 0.60
RAB9A P51151 3/20 0.46
NPC1 O15118 2/20 0.46
CYP1A2 P05177 1/20 0.46
HPGD P15428 1/20 0.46
CYP2C19 P33261 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
RIPK1 Q13546 1/20 0.46
MAPKAPK2 P49137 2/20 0.46
DYRK1B Q9Y463 1/20 0.44
CXCL12 P48061 1/20 0.44
MAPK14 Q16539 2/20 0.43
LMNA P02545 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3328610 1.00 PIM1 (0.60) PIM1CDC7CSNK2A2CLK1GSK3B
SCHEMBL3332906 0.99 PIM1 (0.61) PIM1CDC7CSNK2A2CLK1GSK3B
SCHEMBL3326863 0.97 PIM1 (0.61) PIM1CDC7CSNK2A2CLK1GSK3B
SCHEMBL3329602 0.95 PIM1 (0.64) PIM1CDC7CSNK2A2CLK1GSK3B
SCHEMBL3334901 0.92 PIM1 (0.60) PIM1CDC7CSNK2A2CLK1GSK3B
SCHEMBL3333494 0.92 PIM1 (0.60) PIM1CDC7CSNK2A2CLK1GSK3B
SCHEMBL3334255 0.91 PIM1 (0.59) PIM1CDC7CSNK2A2CLK1GSK3B
SCHEMBL3331149 0.90 PIM1 (0.61) PIM1CDC7CSNK2A2CLK1GSK3B
SCHEMBL3330269 0.89 CDC7 (0.61) PIM1CDC7CSNK2A2CLK1GSK3B
SCHEMBL3329955 0.89 PIM1 (0.61) PIM1CDC7CSNK2A2CLK1GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242129-B2 6-phenylpyrimidinones as PIM modulators EXELIXIS, INC. (US) 2012-08-14 US claimed
US-20100135954-A1 6-Phenylpyrimidinones as PIM Modulators EXELIXIS, INC. (US) 2010-06-03 US claimed
EP-2074103-A1 6-PHENYLPYRIMIDINONES AS PIM MODULATORS Exelixis, Inc. (US) 2009-07-01 EP claimed
WO-2008133955-A1 6-PHENYLPYRIMIDINONES AS PIM MODULATORS EXELIXIS, INC. (US) 2008-11-06 WO claimed
US-8242129-B2 6-phenylpyrimidinones as PIM modulators EXELIXIS, INC. (US) 2012-08-14 US disclosed
US-8242129-B2 6-phenylpyrimidinones as PIM modulators EXELIXIS, INC. (US) 2012-08-14 US disclosed
US-8242129-B2 6-phenylpyrimidinones as PIM modulators EXELIXIS, INC. (US) 2012-08-14 US disclosed
US-20100135954-A1 6-Phenylpyrimidinones as PIM Modulators EXELIXIS, INC. (US) 2010-06-03 US disclosed
US-20100135954-A1 6-Phenylpyrimidinones as PIM Modulators EXELIXIS, INC. (US) 2010-06-03 US disclosed
US-20100135954-A1 6-Phenylpyrimidinones as PIM Modulators EXELIXIS, INC. (US) 2010-06-03 US disclosed
EP-2074103-A1 6-PHENYLPYRIMIDINONES AS PIM MODULATORS Exelixis, Inc. (US) 2009-07-01 EP disclosed
WO-2008133955-A1 6-PHENYLPYRIMIDINONES AS PIM MODULATORS EXELIXIS, INC. (US) 2008-11-06 WO disclosed
WO-2008133955-A1 6-PHENYLPYRIMIDINONES AS PIM MODULATORS EXELIXIS, INC. (US) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100135954-A1 6-Phenylpyrimidinones as PIM Modulators PIM1, PIM2, PIM3 PIM1 1/4885CDC7 3813/4885CSNK2A2 61/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.